Credit Suisse Upgrades Salix (Nasdaq: SLXP) to Outperform
More News related to SLXP
- Salix Pharmaceuticals to Present at Piper Jaffray Conference
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock
- Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
- Salix Pharma (SLXP) Prices 5.5M Share Offering
More News related to Upgrades
- RBC Capital Downgrades Teck Resources Limited (TCK) to Sector Perform
- Wells Fargo Downgrades Regency Centers (REG) to Market Perform; Reducing 2009-2010E FFO/Share
- Goldman Sachs Upgraded US REITS to Neutral; Ups BKD, AVB, GGWPQ, Downgrades KIM
- Collins Stewart Downgrades Genzyme (GENZ) to Hold; Await Additional Execution and Clarity on Troubled Fronts
- Davenport Downgrades Nokia (NOK) to Neutral
Credit Suisse upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Neutral to Outperform.
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States.
Related Categories
UpgradesStocks Mentioned
+0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
